COMMUNIQUÉS West-GlobeNewswire

L’EAACI dévoile des directives en passe de révolutionner la prise en charge des allergies alimentaires induites par les IgE

31/10/2024 - 10:42

Une nouvelle approche fondée sur des données pour la prise en charge des allergies alimentaires ZURICH, 31 oct. 2024 (GLOBE NEWSWIRE) -- L’Académie européenne d’allergologie et d’immunologie clinique (EAACI) a publié la [...]

NRG Therapeutics Selects First Development Candidate, NRG5051, and Secures Grant from The Michael J. Fox Foundation for Development of mPTP Inhibitors to Treat Neurodegenerative Diseases

31/10/2024 - 10:00

First development candidate selected, NRG5051, with potential to treat Parkinson’s and Amyotrophic Lateral Sclerosis (ALS) (also known as Motor Neuron Disease, MND) and other neurodegenerative diseases NRG5051 prevents [...]

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda

31/10/2024 - 09:30

— US$20 million payment based on sales of FRUZAQLA® in metastatic colorectal cancer — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM [...]

Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024

31/10/2024 - 09:00

Data of Blarcamesine confirm upstream SIGMAR1 activation Presented as Late Breaking Oral Communications at Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2024 Oral, once daily blarcamesine meaningfully slowed [...]

NANOBIOTIX to Participate in Multiple Investor Conferences in November

31/10/2024 - 08:30

~ Guggenheim’s Inaugural Healthcare Innovation Conference, Nov 11-13 ~ ~ Stifel Healthcare Conference, Nov 18-19 ~ ~ Jefferies London Healthcare Conference, Nov 19-21 ~ PARIS and CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE [...]

NANOBIOTIX participera à plusieurs conférences investisseurs en novembre

31/10/2024 - 08:30

~ Guggenheim’s Inaugural Healthcare Innovation Conference, 11-13 novembre ~ ~ Stifel Healthcare Conference, 18-19 novembre ~ ~ Jefferies London Healthcare Conference, 19-21 novembre ~ PARIS et CAMBRIDGE, Mass., 31 oct. [...]

Vistin Pharma ASA: Third quarter and YTD 2024 financial results

31/10/2024 - 07:40

Oslo, Norway, 31 st of October 2024 Vistin Pharma ASA (VISTN) today announces the financial results for the third quarter of 2024. Revenue in the third quarter ended at MNOK 106 compared to MNOK 120 in Q3 2023. Sales [...]

Roche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer’s disease

31/10/2024 - 07:15

New data highlight the potential of the Roche Elecsys® Amyloid Plasma Panel and Elecsys ptau181 for ruling out Alzheimer’s disease related amyloid pathology with very good accuracy. In the largest worldwide clinical [...]

Ultimovacs ASA: Invitation to third quarter 2024 results webcast presentation

31/10/2024 - 07:00

Oslo, October 31, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, invites to a webcast presentation of its third quarter 2024 results [...]

New England Journal of Medicine publishes landmark phase III results for Roche’s Itovebi, showing more than doubling of progression-free survival in certain type of HR-positive advanced breast cancer

31/10/2024 - 07:00

Itovebi TM (inavolisib)-based regimen demonstrated a statistically significant and clinically meaningful benefit, reducing the risk of disease worsening or death by 57% compared with palbociclib and fulvestrant alone in [...]

Curevo Presents Positive Shingles Vaccine Outcomes Data

31/10/2024 - 07:00

-- Zero shingles cases after 18.8 months follow-up in 619 patients receiving any dose of amezosvatein, a development-stage adjuvanted subunit vaccine -- Ten shingles cases would have been expected absent vaccination -- [...]

argenx Reports Third Quarter 2024 Financial Results and Provides Business Update

31/10/2024 - 07:00

$573 million in third quarter global net product sales CIDP global expansion on track, with decisions on approval under review in Japan, Europe, China, and Canada Management to host conference call today at 1:30 PM CET [...]

ONWARD ARC-EX® System Named One of TIME's Best Inventions of 2024

31/10/2024 - 06:30

EINDHOVEN, the Netherlands, Oct. 31, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people [...]

Signature de protocoles d’entente entre la PDG d’Avance Clinical, la directrice de sa branche Asie et les principaux sites d’essais cliniques de Corée à la conférence KoNECT 2024

31/10/2024 - 03:54

WAKE FOREST, Caroline du Nord et ADELAIDE, Australie, 31 oct. 2024 (GLOBE NEWSWIRE) -- Avance Clinical , un organisme de recherche sous contrat (ou ORC) leader proposant une gamme complète de services à l’échelle [...]

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million

31/10/2024 - 03:29

Includes initial funding of approximately $5 million, as well as the option for additional proceeds of approximately $5 million NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“ [...]

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

31/10/2024 - 02:00

ICoN-1 study presentation planned November 1 at NTM Symposium Australia Study is cleared by health authorities to proceed in Australia, U.S., Japan and South Korea, with Taiwan anticipated by end of year DANBURY, Conn [...]

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

31/10/2024 - 00:30

-New testing method highlights link between protofibrils and biomarkers for neurodegeneration- -Patient and caregiver perspectives on five-year treatment with lecanemab - - Utilization of blood biomarkers to predict [...]

Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024

31/10/2024 - 00:11

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the [...]

Greenhouse Treatment Center Joins Elite Group of Veteran Ready Addiction Treatment Providers with New PsychArmor Certification

30/10/2024 - 23:21

GRAND PRAIRIE, Texas, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Greenhouse Treatment Center recently achieved Veteran Ready Certification from PsychArmor, a nonprofit organization dedicated to military culture training. This [...]